These results could pave the way toward SLC4A4-based therapeutic strategies that mitigate tumor acidosis, abate immunosuppression, increase CD8+ T cell fitness and sensitize PDAC to the current immunotherapeutic regimens, an unmet clinical need for far. Here, CD8A is linked to neoplasm.